Endpoints News

cAMPfield Therapeutics raises $180M		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T W Thu F

21 May, 2026

LGBTQ+ diversity drives innovation in biopharma — but transgender and non-binary professionals face rising challenges. Endpoints is going live with our fourth annual special report celebrating the honorees giving voice and visibility while forging ahead across life sciences. Join us.

Spotlight

In Focus

Fetal gene therapy inches closer. Will embryo editing follow?

news

Lilly’s triple agonist still leads among late-stage obesity assets

Exclusive: Another I&I biotech, Gerhart-led cAMPfield, draws top-tier investors in $180M Series A

Post-Hoc: The next big pharma company will come from China

May 28

11:30 am ET

From signal to strategy: The future of systemic viral immunotherapy in GI tumors and Oncolytics Biotech

in case you missed it

Driven by GLP-1s, pharma’s relationship with consumers is starting to change

Parabilis reveals IPO plans the day after Regeneron deal as listings heat up

GHO Capital, CBC Group to merge, forming what could be the largest healthcare specialist investor

News Briefing

Pfizer's next-gen pneumonia shot beats Prevnar 20; Relay targets $175M

US enlists small biotech for experimental Ebola treatment

US Health Secretary Kennedy backs away from some recent changes to CDC vaccine panel

Lilly has more data for its triple-G agonist today and, according to an analysis by Elizabeth Cairns, the candidate has the strongest data yet in a Phase 3 trial that recruits obesity-only patients. Read more here.

Reynald Castaneda

Deputy Editor, Endpoints News

2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com

Endpoints Studio
Endpoints Webinars

Endpoints Events
Biopharma Jobs

Worldwide made. Thanks for reading.

Unsubscribe preferences